Candidiasis - Pipeline Review, H2 2017

Date: August 22, 2017
Pages: 161
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C1A9F76F89FEN
Leaflet:

Download PDF Leaflet

Candidiasis - Pipeline Review, H2 2017
Candidiasis - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Candidiasis - Pipeline Review, H2 2017, provides an overview of the Candidiasis (Infectious Disease) pipeline landscape.

Candidiasis is caused by infection with species of the genus Candida, predominantly with Candida albicans. A Candida infection of the skin appears as a clearly defined patch of red, itchy skin, often leaking fluid. Scabs and pustules may be seen around the edge of the rash. It will usually be found in areas such as the groin, the folds of the buttocks, between the breasts, toes, or fingers, and in the navel. Treatment includes anti fungal drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Candidiasis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Candidiasis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Candidiasis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Candidiasis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 7, 2, 22, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 10 and 9 molecules, respectively.

Candidiasis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Candidiasis (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Candidiasis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Candidiasis (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Candidiasis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Candidiasis (Infectious Disease)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Candidiasis (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Candidiasis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Candidiasis - Overview
Candidiasis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Candidiasis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Candidiasis - Companies Involved in Therapeutics Development
Amplyx Pharmaceuticals Inc
Bakker Medical Srl
Beta Pharma Inc
Biomar Microbial Technologies
Bionex Pharmaceuticals LLC
Biosergen AS
Cidara Therapeutics Inc
Dermala Inc
Gedea Biotech AB
General Biologicals Corp
Grupo Ferrer Internacional SA
Hsiri Therapeutics LLC
iCo Therapeutics Inc.
ImmunoClin Corp
Matinas BioPharma Holdings Inc
Nanomerics Ltd
Novabiotics Ltd
NovaDigm Therapeutics Inc
Novartis AG
Onxeo SA
Scynexis Inc
Sealife PHARMA GMBH
Viamet Pharmaceuticals Inc
Visterra Inc
Wellstat Vaccines LLC
Candidiasis - Drug Profiles
(clotrimazole + diclofenac sodium) - Drug Profile
61894700 - DRUG PROFILE
AC-17 - Drug Profile
amphotericin B - Drug Profile
amphotericin B - Drug Profile
amphotericin B - Drug Profile
Amphotericin B sodium - Drug Profile
Antibody to Target Ece1 for Candidiasis - Drug Profile
APX-001 - Drug Profile
APX-001A - Drug Profile
arasertaconazole - Drug Profile
B-4010 - Drug Profile
BL-5923 - Drug Profile
BSG-005 - Drug Profile
candidiasis vaccine - Drug Profile
CD-101 - Drug Profile
Cellullar Immunotherapy for Viral Infections and Fungal Infections - Drug Profile
CLX-159 - Drug Profile
CSA-13 - Drug Profile
Drug for Candidiasis - Drug Profile
Drug for Oral Candidiasis - Drug Profile
Forazoline A - Drug Profile
GA-101 - Drug Profile
iCo-010 - Drug Profile
interleukin-22 - Drug Profile
JSM-11 - Drug Profile
KSL-W - Drug Profile
miconazole nitrate - Drug Profile
Monoclonal Antibodies for Candidiasis - Drug Profile
Monoclonal Antibody for Candidiasis - Drug Profile
Monoclonal Antibody for Candidiasis and Gram-Positive Bacterial Infections - Drug Profile
mutanobactin A - Drug Profile
NDV-3 - Drug Profile
NDV-3A - Drug Profile
NP-339 - Drug Profile
obliquumol - Drug Profile
Occidiofungin - Drug Profile
P-113Du - Drug Profile
P-113Tri - Drug Profile
PAC-113 - Drug Profile
Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile
Prof-002 - Drug Profile
Recombinant Enzyme for Candidiasis - Drug Profile
Recombinant Peptides for Oropharyngeal Candidiasis - Drug Profile
SCY-078 - Drug Profile
SLP-0901 - Drug Profile
SLP-0904 - Drug Profile
Small Molecule for Bacterial Vaginosis and Candidiasis - Drug Profile
Small Molecule for Candidiasis - Drug Profile
Small Molecule for Fungal Infections - Drug Profile
Small Molecules for Aspergillosis and Candidiasis - Drug Profile
Small Molecules for Candidiasis - Drug Profile
Small Molecules for Candidiasis - Drug Profile
Small Molecules for Candidiasis - Drug Profile
Small Molecules for Fungal Infections - Drug Profile
Small Molecules for Fungal Infections - Drug Profile
Small Molecules for Systemic Candidiasis - Drug Profile
Synthetic Peptide to Inhibit CBL-B for Candidiasis - Drug Profile
Synthetic Peptides for Candidiasis - Drug Profile
Synthetic Peptides for Infections Diseases and Oncology - Drug Profile
TOL-463 - Drug Profile
Vaccine to Target Ece1 for Candidiasis - Drug Profile
Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile
VIS-FNG - Drug Profile
voriconazole - Drug Profile
VT-1129 - Drug Profile
VT-1161 - Drug Profile
VT-1598 - Drug Profile
Candidiasis - Dormant Projects
Candidiasis - Discontinued Products
Candidiasis - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Candidiasis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Candidiasis - Pipeline by Amplyx Pharmaceuticals Inc, H2 2017
Candidiasis - Pipeline by Bakker Medical Srl, H2 2017
Candidiasis - Pipeline by Beta Pharma Inc, H2 2017
Candidiasis - Pipeline by Biomar Microbial Technologies, H2 2017
Candidiasis - Pipeline by Bionex Pharmaceuticals LLC, H2 2017
Candidiasis - Pipeline by Biosergen AS, H2 2017
Candidiasis - Pipeline by Cidara Therapeutics Inc, H2 2017
Candidiasis - Pipeline by Dermala Inc, H2 2017
Candidiasis - Pipeline by Gedea Biotech AB, H2 2017
Candidiasis - Pipeline by General Biologicals Corp, H2 2017
Candidiasis - Pipeline by Grupo Ferrer Internacional SA, H2 2017
Candidiasis - Pipeline by Hsiri Therapeutics LLC, H2 2017
Candidiasis - Pipeline by iCo Therapeutics Inc., H2 2017
Candidiasis - Pipeline by ImmunoClin Corp, H2 2017
Candidiasis - Pipeline by Matinas BioPharma Holdings Inc, H2 2017
Candidiasis - Pipeline by Nanomerics Ltd, H2 2017
Candidiasis - Pipeline by Novabiotics Ltd, H2 2017
Candidiasis - Pipeline by NovaDigm Therapeutics Inc, H2 2017
Candidiasis - Pipeline by Novartis AG, H2 2017
Candidiasis - Pipeline by Onxeo SA, H2 2017
Candidiasis - Pipeline by Scynexis Inc, H2 2017
Candidiasis - Pipeline by Sealife PHARMA GMBH, H2 2017
Candidiasis - Pipeline by Viamet Pharmaceuticals Inc, H2 2017
Candidiasis - Pipeline by Visterra Inc, H2 2017
Candidiasis - Pipeline by Wellstat Vaccines LLC, H2 2017
Candidiasis - Dormant Projects, H2 2017
Candidiasis - Dormant Projects, H2 2017 (Contd..1), H2 2017
Candidiasis - Dormant Projects, H2 2017 (Contd..2), H2 2017
Candidiasis - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Candidiasis, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Top 10 Routes of Administration, H2 2017
Number of Products by Stage and Top 10 Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Amplyx Pharmaceuticals Inc
Bakker Medical Srl
Beta Pharma Inc
Biomar Microbial Technologies
Bionex Pharmaceuticals LLC
Biosergen AS
Cidara Therapeutics Inc
Dermala Inc
Gedea Biotech AB
General Biologicals Corp
Grupo Ferrer Internacional SA
Hsiri Therapeutics LLC
iCo Therapeutics Inc.
ImmunoClin Corp
Matinas BioPharma Holdings Inc
Nanomerics Ltd
Novabiotics Ltd
NovaDigm Therapeutics Inc
Novartis AG
Onxeo SA
Scynexis Inc
Sealife PHARMA GMBH
Viamet Pharmaceuticals Inc
Visterra Inc
Wellstat Vaccines LLC
Skip to top


Vulvovaginal Candidiasis - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 63 pages

Ask Your Question

Candidiasis - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: